表 2.

AMH水平与SLE患者临床和实验室指标的关系

Relationship between AMH and clinical symptoms and laboratory parameters in SLE patients

Parameters	AMH normal (n=59)	AMH decreased (n=48)	U/ χ2 value	P value
AMH, anti-Müllerian hormone; SLE, systemic lupus erythematosus; Anti-dsDNA, anti-double-stranded DNA; Anti-Sm, anti-Smith; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; C3, complement 3; C4, complement 4; MMF, mycophenolate mofetil; CTX, cyclophosphamide; RTX, rituximab; SLEDAI-2000, systemic lupus erythematosus disease activity index 2000.
Age/years, M(P25, P75)	29.00 (24.00, 32.00)	33.00 (28.00, 36.00)	855.0	0.001
Disease duration/years, M (P25, P75)	2.00 (0.50, 7.00)	6.50 (3.00, 12.00)	860.5	< 0.001
Clinical symptoms
Rash, n (%)	33 (55.9)	31 (64.6)	0.824	0.364
Photosensitivity, n (%)	9 (15.3)	9 (18.8)	0.231	0.631
Oral ulcers, n (%)	8 (13.6)	9 (18.8)	0.534	0.465
Arthritis, n (%)	32 (54.2)	30 (62.5)	0.742	0.389
Serositis, n (%)	19 (32.2)	12 (25.0)	0.667	0.414
Renal disorder, n (%)	30 (50.8)	24 (50.0)	0.008	0.931
Neurologic disorder, n (%)	14 (23.7)	16 (33.3)	1.210	0.271
Hematologic disorder, n (%)	29 (49.2)	25 (52.1)	0.091	0.763
Laboratory parameters
Antinuclear antibody positive, n (%)	57 (96.6)	44 (91.7)	1.559	0.459
Anti-dsDNA antibody positive, n (%)	37 (62.7)	28 (58.3)	0.213	0.645
Anti-Sm antibody positive, n (%)	8 (13.6)	11 (22.9)	1.587	0.208
IgA, M (P25, P75)	2.285 (1.758, 3.245)	2.800 (1.600, 3.570)	1 236.0	0.414
IgG, M (P25, P75)	13.70 (10.90, 17.54)	13.68 (9.07, 17.00)	1 322.0	0.794
IgM, M (P25, P75)	1.085 (0.690, 1.450)	0.826 (0.470, 1.340)	1 078.0	0.066
C3, M (P25, P75)	0.716 (0.528, 0.437)	0.610 (0.437, 0.943)	1 236.0	0.323
C4, M (P25, P75)	0.121 (0.080, 0.237)	0.140 (0.080, 0.214)	1 345.0	0.768
Immunosuppressant
MMF, n (%)	25 (42.4)	20 (41.7)	0.490	0.783
CTX, n (%)	2 (3.4)	3 (6.3)	0.003	0.953
Biologics
RTX, n (%)	12/53 (20.3)	8/42 (16.7)	0.452	0.502
Telitacicept, n (%)	12/53 (20.3)	7/42 (14.6)	0.817	0.366
SLEDAI-2000, M(P25, P75)	9.0 (5.0, 14.0)	9.0 (5.3, 14.0)	1 333.0	0.605